TRS003 (bevacizumab biosimilar)
/ Zhejiang Teruisi Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 18, 2022
A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC
(clinicaltrials.gov)
- P3 | N=126 | Not yet recruiting | Sponsor: Zhejiang Teruisi Pharmaceutical Inc.
New P3 trial • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF
August 31, 2020
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
(clinicaltrials.gov)
- P3; N=608; Recruiting; Sponsor: Zhejiang Teruisi Pharmaceutical Inc.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
June 04, 2020
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
(clinicaltrials.gov)
- P3; N=608; Not yet recruiting; Sponsor: Zhejiang Teruisi Pharmaceutical Inc.
Clinical • New P3 trial • Gastrointestinal Cancer • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Thoracic Cancer • ALK
1 to 3
Of
3
Go to page
1